癌症研究
肺癌
癌变
下调和上调
癌症
免疫系统
免疫抑制
免疫疗法
炎症
腺癌
医学
免疫学
生物
内科学
基因
生物化学
作者
Jiawei Yue,Hui Guo,Peng Xu,Jinhong Ma,Yue Wu
出处
期刊:PubMed
日期:2023-01-01
卷期号:13 (6): 2426-2438
被引量:1
摘要
Lung cancer is the most common cancer type with poor prognosis. While G protein-coupled receptor 35 (GPR35) is a potent stimulator of tumor growth, group 2 innate lymphoid cells (ILC2) have shown dual effects in tumorigenesis. Intriguingly, inflammation induced GPR35 activation leads to an upregulation in the markers associated with ILC2. Here, we reported that GPR35 knockout mice exhibited a significantly reduced tumor growth and altered immune infiltration in tumors. Furthermore, activating GPR35 in different mouse models promoted tumor development by enhancing the production of IL-5 and IL-13, thereby facilitating the formation of the ILC2-MDSC axis. Moreover, we found that GPR35 was a poor prognostic factor in patients with lung adenocarcinoma. Together, our findings suggest the potential application of targeting GPR35 in cancer immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI